JPMorgan Chase & Co. Grows Position in Shattuck Labs, Inc. (NASDAQ:STTK)

JPMorgan Chase & Co. grew its stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 63.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,533 shares of the company’s stock after buying an additional 10,667 shares during the period. JPMorgan Chase & Co. owned 0.06% of Shattuck Labs worth $96,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of STTK. Dimensional Fund Advisors LP boosted its holdings in shares of Shattuck Labs by 8.5% during the second quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company’s stock worth $266,000 after purchasing an additional 5,397 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Shattuck Labs by 0.9% during the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after purchasing an additional 8,133 shares during the last quarter. Atom Investors LP acquired a new stake in shares of Shattuck Labs during the third quarter worth $35,000. Readystate Asset Management LP acquired a new stake in shares of Shattuck Labs during the third quarter worth $39,000. Finally, MetLife Investment Management LLC boosted its holdings in shares of Shattuck Labs by 129.1% during the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the last quarter. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Down 7.2 %

Shares of STTK stock opened at $1.16 on Monday. The business has a 50 day moving average of $1.17 and a two-hundred day moving average of $2.15. Shattuck Labs, Inc. has a 52 week low of $0.94 and a 52 week high of $11.76. The company has a market cap of $55.38 million, a P/E ratio of -0.76 and a beta of 1.71.

Insider Transactions at Shattuck Labs

In related news, Director Redmile Group, Llc purchased 133,371 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were bought at an average price of $1.25 per share, with a total value of $166,713.75. Following the completion of the acquisition, the director now owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This represents a 2.47 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a report on Thursday, November 14th. HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Shattuck Labs presently has an average rating of “Hold” and an average price target of $8.67.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.